Nothing Special   »   [go: up one dir, main page]

EA201171088A1 - Лечение дискинезии при различных расстройствах - Google Patents

Лечение дискинезии при различных расстройствах

Info

Publication number
EA201171088A1
EA201171088A1 EA201171088A EA201171088A EA201171088A1 EA 201171088 A1 EA201171088 A1 EA 201171088A1 EA 201171088 A EA201171088 A EA 201171088A EA 201171088 A EA201171088 A EA 201171088A EA 201171088 A1 EA201171088 A1 EA 201171088A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
diskinesia
different disorders
dyskinesia
disease
Prior art date
Application number
EA201171088A
Other languages
English (en)
Other versions
EA023778B1 (ru
Inventor
Хокан Викстрем
Мортен Йергенсен
Нильс Мерк
Дженнифер Ларсен
Ларс Торуп
Бенни Банг-Андерсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171088(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA201171088A1 publication Critical patent/EA201171088A1/ru
Publication of EA023778B1 publication Critical patent/EA023778B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Впервые описываются способы лечения болезни Паркинсона при поддержании низкого уровня развития дискинезии и способы реверсирования дискинезии, включающие в себя введение терапевтически эффективного количества соединения по изобретению. Далее, настоящее изобретение относится к рецептурам и фармацевтическим композициям упомянутых соединений для производства лекарственных средств для лечения указанного заболевания.
EA201171088A 2009-02-27 2010-02-26 Лечение дискинезии при различных расстройствах EA023778B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200900281 2009-02-27
DKPA200900273 2009-02-27
DKPA200900280 2009-02-27
PCT/DK2010/050051 WO2010097092A1 (en) 2009-02-27 2010-02-26 Treatment of dyskinesia related disorders

Publications (2)

Publication Number Publication Date
EA201171088A1 true EA201171088A1 (ru) 2012-02-28
EA023778B1 EA023778B1 (ru) 2016-07-29

Family

ID=42060693

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171088A EA023778B1 (ru) 2009-02-27 2010-02-26 Лечение дискинезии при различных расстройствах

Country Status (20)

Country Link
US (1) US20120108624A1 (ru)
EP (2) EP3653210A1 (ru)
JP (1) JP5738775B2 (ru)
KR (1) KR101700978B1 (ru)
CN (1) CN102333531B (ru)
AR (1) AR075625A1 (ru)
AU (1) AU2010217059B2 (ru)
BR (1) BRPI1007017A2 (ru)
CA (1) CA2751322C (ru)
CL (1) CL2011002102A1 (ru)
CO (1) CO6410297A2 (ru)
EA (1) EA023778B1 (ru)
HK (1) HK1166472A1 (ru)
IL (1) IL213502A (ru)
MX (1) MX340138B (ru)
NZ (1) NZ594264A (ru)
SG (1) SG174163A1 (ru)
TW (1) TW201036949A (ru)
WO (1) WO2010097092A1 (ru)
ZA (1) ZA201106294B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20227446B (en) 2017-11-24 2022-12-12 H Lundbeck As New catecholamine prodrugs for use in treatment of parkinson's disease
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) * 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US20220220077A1 (en) 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US20220213071A1 (en) 2019-05-21 2022-07-07 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP2022533914A (ja) 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
WO2022106352A1 (en) 2020-11-17 2022-05-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2023208869A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
AU2023259559A1 (en) 2022-04-25 2024-10-31 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001438D0 (sv) * 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
AR075625A1 (es) 2011-04-20
MX2011008944A (es) 2011-09-15
US20120108624A1 (en) 2012-05-03
CN102333531B (zh) 2013-11-06
KR20110132340A (ko) 2011-12-07
IL213502A (en) 2017-02-28
BRPI1007017A2 (pt) 2016-03-29
CA2751322C (en) 2017-10-31
ZA201106294B (en) 2012-10-31
AU2010217059B2 (en) 2012-08-30
MX340138B (es) 2016-06-28
CO6410297A2 (es) 2012-03-30
JP5738775B2 (ja) 2015-06-24
SG174163A1 (en) 2011-10-28
EP2400967A1 (en) 2012-01-04
TW201036949A (en) 2010-10-16
JP2012519157A (ja) 2012-08-23
CN102333531A (zh) 2012-01-25
CL2011002102A1 (es) 2012-07-20
HK1166472A1 (en) 2012-11-02
NZ594264A (en) 2013-11-29
IL213502A0 (en) 2011-07-31
AU2010217059A1 (en) 2011-08-11
WO2010097092A1 (en) 2010-09-02
EA023778B1 (ru) 2016-07-29
EP2400967B1 (en) 2019-08-14
EP3653210A1 (en) 2020-05-20
KR101700978B1 (ko) 2017-01-31
CA2751322A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MX2009010407A (es) Derivados fluorados de deferiprona.
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
WO2013040227A3 (en) Therapeutic compounds
WO2011023367A3 (en) Bisphosphonate-prodrugs
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU